#ESMO24 roundup: New data on Amgen’s PRMT5 inhibitor seem lackluster, and Jazz’s HER2 antibody
On Sunday evening, abstracts from the European Society for Medical Oncology were released. While some of oncology’s most exciting recent data were …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
